Hepatic Encephalopathy in Patients with Cirrhosis

[1]  S. Sherlock,et al.  Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. , 1980, Gastroenterology.

[2]  J. Daurès,et al.  [Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial]. , 1994, Gastroenterologie clinique et biologique.

[3]  S. Riordan,et al.  Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis , 2004, Hepatology.

[4]  A. Lockwood,et al.  Positron‐emission tomographic localization of abnormalities of brain metabolism in patients with minimal hepatic encephalopathy , 1993, Hepatology.

[5]  M. Morgan,et al.  Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: A double‐blind, randomized trial , 1987, Hepatology.

[6]  O. Riggio,et al.  Simple tools for complex syndromes: a three-level difficulty test for hepatic encephalopathy. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[7]  G. Marchesini,et al.  Branched-chain amino acids for people with hepatic encephalopathy. , 2017, The Cochrane database of systematic reviews.

[8]  C. Leevy,et al.  Rifaximin treatment in hepatic encephalopathy. , 2010, The New England journal of medicine.

[9]  A. Chhibber,et al.  The hyperventilation of cirrhosis: Progesterone and estradiol effects , 1997, Hepatology.

[10]  Yong He,et al.  Partial pressure of NH₃ in cirrhotic patients with and without hepatic encephalopathy. , 2011, Journal of gastrointestinal and liver diseases : JGLD.

[11]  Lars Timmermann,et al.  Critical flicker frequency for quantification of low‐grade hepatic encephalopathy , 2002, Hepatology.

[12]  B. Sharma,et al.  Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. , 2007, Journal of hepatology.

[13]  J. Guérit,et al.  Spectral versus visual EEG analysis in mild hepatic encephalopathy , 1999, Clinical Neurophysiology.

[14]  D. Freides,et al.  Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism. , 1978, Gastroenterology.

[15]  R. Butterworth,et al.  The neurosteroid system: Implication in the pathophysiology of hepatic encephalopathy , 2008, Neurochemistry International.

[16]  J. Canales,et al.  Chronic hyperammonemia alters motor and neurochemical responses to activation of group i metabotropic glutamate receptors in the nucleus accumbens in rats in vivo , 2003, Neurobiology of Disease.

[17]  G. Barbarini,et al.  Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: An italian multicenter double‐blind, placebo‐controlled, cross‐over study , 1998, Hepatology.

[18]  R. Butterworth,et al.  Effect of ammonium ions on synaptic transmission in the mammalian central nervous system , 1992, Progress in Neurobiology.

[19]  R. Butterworth,et al.  Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy , 1995, Metabolic Brain Disease.

[20]  Y. Archibald,et al.  The encephalopathy associated with septic illness. , 1990, Clinical and investigative medicine. Medecine clinique et experimentale.

[21]  J. Wiltfang,et al.  Neurophysiological assessment of early hepatic encephalopathy. , 1990, Electroencephalography and clinical neurophysiology.

[22]  I. Ahmad,et al.  L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy. , 2008, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[23]  R. Butterworth,et al.  Increased activities of MAOA and MAOB in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy , 1993, Brain Research.

[24]  C. Strassburg,et al.  Cerebral white matter lesions in patients with cirrhosis – causative for hepatic encephalopathy or bystanders? , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[25]  C. Strassburg,et al.  Cirrhosis-related Parkinsonism: prevalence, mechanisms and response to treatments. , 2013, Journal of hepatology.

[26]  A. Webster,et al.  Probiotics for people with hepatic encephalopathy. , 2017, The Cochrane database of systematic reviews.

[27]  P. Lucatelli,et al.  Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft. , 2009, AJR. American journal of roentgenology.

[28]  R. Butterworth,et al.  Selective loss of pallidal dopamine D2 receptor density in hepatic encephalopathy , 1993, Neuroscience Letters.

[29]  M. Merli,et al.  Increased risk of cognitive impairment in cirrhotic patients with bacterial infections. , 2013, Journal of hepatology.

[30]  À. Rovira,et al.  1H Magnetic Resonance in the Study of Hepatic Encephalopathy in Humans , 2002, Metabolic Brain Disease.

[31]  M. Morgan,et al.  Methods for Diagnosing Hepatic Encephalopathy in Patients with Cirrhosis: A Multidimensional Approach , 2004, Metabolic Brain Disease.

[32]  T. Barrientos-Gutiérrez,et al.  A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy , 2013, Nutrition Journal.

[33]  E. Berry,et al.  Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. , 2009, Journal of hepatology.

[34]  C. McClain,et al.  Psychomotor performance defects in cirrhotic patients without overt encephalopathy. , 1980, Archives of internal medicine.

[35]  D. V. van Thiel,et al.  Subclinical hepatic encephalopathy. Comparison before and after orthotopic liver transplantation. , 1990, Transplantation.

[36]  S. Sherlock,et al.  The electroencephalograph in liver disease. , 1957, Lancet.

[37]  Karl Zilles,et al.  Neurotransmitter Receptor Imbalances in Motor Cortex and Basal Ganglia in Hepatic Encephalopathy , 2009, Cellular Physiology and Biochemistry.

[38]  Manuel Romero-Gómez,et al.  Value of the critical flicker frequency in patients with minimal hepatic encephalopathy , 2007, Hepatology.

[39]  F. X. Aymerich,et al.  Decreased white matter lesion volume and improved cognitive function after liver transplantation , 2007, Hepatology.

[40]  P. Malfertheiner,et al.  Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. , 1998, Journal of hepatology.

[41]  R. Hughes,et al.  Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis , 2010, Hepatology.

[42]  K. Weissenborn.  Diagnosis of Encephalopathy , 1998, Digestion.

[43]  S. Dasarathy,et al.  Sodium benzoate in the treatment of acute hepatic encephalopathy: A double‐blind randomized trial , 1992, Hepatology.

[44]  M. Morgan,et al.  Spatio-temporal decomposition of the electroencephalogram in patients with cirrhosis. , 2007, Journal of hepatology.

[45]  P. V. Leeuwen,et al.  NEW MODE OF ACTION FOR LACTULOSE , 1988, The Lancet.

[46]  À. Rovira,et al.  Brain magnetic resonance in hepatic encephalopathy. , 2014, Seminars in ultrasound, CT, and MR.

[47]  M. Hashizume,et al.  Portosystemic encephalopathy treated with balloon-occluded retrograde transvenous obliteration. , 1995, The American journal of gastroenterology.

[48]  Philip Wong,et al.  Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver , 2014, Hepatology.

[49]  P. Ott,et al.  Cerebral effects of ammonia in liver disease: current hypotheses , 2014, Metabolic Brain Disease.

[50]  G. Kircheis,et al.  Therapeutic efficacy of L‐ornithine‐L‐aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo‐controlled, double‐blind study , 1997, Hepatology.

[51]  R. Maffei,et al.  Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. , 1992, Hepato-gastroenterology.

[52]  S. Taylor-Robinson,et al.  Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy , 1994, Metabolic Brain Disease.

[53]  J. Bajaj,et al.  Diagnosis of Minimal Hepatic Encephalopathy Using Stroop EncephalApp: A Multicenter US-Based, Norm-Based Study , 2016, The American Journal of Gastroenterology.

[54]  R. Jalan,et al.  Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats. , 2014, Journal of hepatology.

[55]  R. Butterworth,et al.  Diencephalic and cerebellar pathology in alcoholic and nonalcoholic patients with end‐stage liver disease , 1997, Hepatology.

[56]  P. Angeli,et al.  Covert hepatic encephalopathy: agreement and predictive validity of different indices. , 2014, World journal of gastroenterology.

[57]  Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity? , 2001 .

[58]  M. Morgan,et al.  Bromocriptine-associated ototoxicity , 1984, The Journal of Laryngology & Otology.

[59]  C. Zwingmann,et al.  L‐ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats , 2009, Hepatology.

[60]  H. Hinterhuber,et al.  Incomplete improvement of visuo‐motor deficits in patients with minimal hepatic encephalopathy after liver transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[61]  V. Felipo,et al.  Brain cholinergic impairment in liver failure , 2008, Brain : a journal of neurology.

[62]  H. Wedemeyer,et al.  The role of zinc in liver cirrhosis. , 2016 .

[63]  M. Malaguarnera,et al.  Effects of L-carnitine in patients with hepatic encephalopathy. , 2005, World journal of gastroenterology.

[64]  N. Accornero,et al.  High prevalence of spontaneous portal‐systemic shunts in persistent hepatic encephalopathy: A case‐control study , 2005, Hepatology.

[65]  B. Jennett,et al.  Assessment of coma and impaired consciousness. A practical scale. , 1974, Lancet.

[66]  P. Angeli,et al.  Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests , 1999, Hepatology.

[67]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[68]  Alan H. Lockwood,et al.  Blood Ammonia Levels and Hepatic Encephalopathy , 2004, Metabolic Brain Disease.

[69]  R. Butterworth,et al.  The nutritional management of hepatic encephalopathy in patients with cirrhosis: International society for hepatic encephalopathy and nitrogen metabolism consensus , 2013, Hepatology.

[70]  F. Challenger,et al.  Methyl mercaptan in relation to foetor hepaticus. , 1955, The Biochemical journal.

[71]  P. Desjardins,et al.  Evidence for oxidative/nitrosative stress in the pathogenesis of hepatic encephalopathy , 2010, Metabolic Brain Disease.

[72]  K. Demır,et al.  Are Acquired Hepatocerebral Degeneration and Hepatic Myelopathy Reversible? , 2009, Journal of clinical gastroenterology.

[73]  S. Taylor-Robinson,et al.  A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy , 2012, Metabolic Brain Disease.

[74]  M. Morgan.  Cerebral Magnetic Resonance Imaging in Patients with Chronic Liver Disease , 1998, Metabolic Brain Disease.

[75]  Klaus P. Ebmeier,et al.  Regional cerebral blood flow and cognitive function in patients with chronic liver disease , 1991, The Lancet.

[76]  R Fischer,et al.  Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? , 2000, Journal of hepatology.

[77]  M. Manns,et al.  Liver transplantation improves hepatic myelopathy: evidence by three cases. , 2003, Gastroenterology.

[78]  Y. Miyata,et al.  Hepatic encephalopathy and reversible cortical blindness. , 1988, American Journal of Gastroenterology.

[79]  P. Bisiacchi,et al.  Improving the inhibitory control task to detect minimal hepatic encephalopathy. , 2010, Gastroenterology.

[80]  K. Takeda,et al.  Improvement of regional cerebral blood flow after treatment with branched‐chain amino acid solutions in patients with cirrhosis , 2003, European journal of gastroenterology & hepatology.

[81]  A. Schnitzler,et al.  Diagnostic and prognostic values of critical flicker frequency determination as new diagnostic tool for objective HE evaluation in patients undergoing TIPS implantation , 2009, European journal of gastroenterology & hepatology.

[82]  B. Sharma,et al.  Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. , 2009, Gastroenterology.

[83]  Beiwen Zheng,et al.  Alterations of the human gut microbiome in liver cirrhosis , 2014, Nature.

[84]  F. Glocker,et al.  Portosystemic myelopathy: Spastic paraparesis after portosystemic shunting , 2006, Scandinavian journal of gastroenterology.

[85]  Edward T. Bullmore,et al.  Functional brain network changes associated with clinical and biochemical measures of the severity of hepatic encephalopathy , 2015, NeuroImage.

[86]  A. Lockwood,et al.  Cerebral Ammonia Metabolism in Patients with Severe Liver Disease and Minimal Hepatic Encephalopathy , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[87]  Ritesh Agarwal,et al.  Lactulose improves cognitive functions and health‐related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy , 2007, Hepatology.

[88]  C. Leevy,et al.  Hospitalizations During the Use of Rifaximin Versus Lactulose for the Treatment of Hepatic Encephalopathy , 2007, Digestive Diseases and Sciences.

[89]  William M. Lee,et al.  Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. , 2010, Gastroenterology.

[90]  R. Jalan,et al.  Interorgan ammonia metabolism in liver failure: the basis of current and future therapies , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[91]  H. Figulla,et al.  Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Clinical, laboratory, psychometric, and electroencephalographic investigations , 1998, Hepatology.

[92]  Michael L Volk,et al.  Hospital Readmissions Among Patients With Decompensated Cirrhosis , 2012, The American Journal of Gastroenterology.

[93]  S. Saab,et al.  Probiotics are helpful in hepatic encephalopathy: a meta‐analysis of randomized trials , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[94]  Masahiko Kato,et al.  Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[95]  R. Gish,et al.  Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[96]  R. Butterworth,et al.  Alterations of [3H]8-OH-DPAT and [3H]ketanserin binding sites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy , 1994, Neuroscience Letters.

[97]  R. Adams,et al.  THE ACQUIRED (NON-WILSONIAN) TYPE OF CHRONIC HEPATOCEREBRAL DEGENERATION , 1965, Medicine.

[98]  A. Read,et al.  Lactobacillus acidophilus (Enpac) in Treatment of Hepatic Encephalopathy , 1966, British medical journal.

[99]  A. McCullough,et al.  Late evening snack: Exploiting a period of anabolic opportunity in cirrhosis , 2012, Journal of gastroenterology and hepatology.

[100]  P. Amodio,et al.  Neurocognitive-neurological complications of liver transplantation: a review , 2010, Metabolic Brain Disease.

[101]  M. Ferraz,et al.  A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment. , 2009, Arquivos de gastroenterologia.

[102]  F. Moeller,et al.  Liver transplantation significantly improves global functioning and cerebral processing , 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[103]  F. Marotta,et al.  Endotoxinemia and benzodiazepine-like substances in compensated cirrhotic patients: a randomized study comparing the effect of rifaximine alone and in association with a symbiotic preparation. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[104]  F. X. Aymerich,et al.  A Long-Term Study of Changes in the Volume of Brain Ventricles and White Matter Lesions After Successful Liver Transplantation , 2010, Transplantation.

[105]  M. Holeček.  Three targets of branched-chain amino acid supplementation in the treatment of liver disease. , 2010, Nutrition.

[106]  R. Gish,et al.  Sodium benzoate for treatment of hepatic encephalopathy. , 2013, Gastroenterology & hepatology.

[107]  M. Morgan,et al.  Bromocriptine-associated hyponatraemia in cirrhosis. , 1982, British medical journal.

[108]  J. Chalk,et al.  Improvement in chronic hepatocerebral degeneration following liver transplantation. , 1990, Gastroenterology.

[109]  D. Larkman,et al.  Current and future applications of magnetic resonance imaging and spectroscopy of the brain in hepatic encephalopathy. , 2006, World journal of gastroenterology.

[110]  J. Córdoba,et al.  Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence , 2010, Metabolic Brain Disease.

[111]  J. Daurès,et al.  Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: Results of a meta‐analysis , 1992, Hepatology.

[112]  N. Pavese,et al.  Brain metabolism in patients with hepatic encephalopathy studied by PET and MR. , 2013, Archives of biochemistry and biophysics.

[113]  N. Bass.  Review article: the current pharmacological therapies for hepatic encephalopathy , 2007, Alimentary pharmacology & therapeutics.

[114]  R. Butterworth,et al.  L-Ornithine-L-Aspartate in Experimental Portal-Systemic Encephalopathy: Therapeutic Efficacy and Mechanism of Action , 1998, Metabolic Brain Disease.

[115]  M. Uribe,et al.  Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal‐systemic encephalopathy: A double‐blind, randomized clinical trial , 1987, Hepatology.

[116]  M. Morgan,et al.  Letter: stepwise diagnosis in covert hepatic encephalopathy – critical flicker frequency and MELD‐score as a first‐step approach. Replication and pitfalls , 2017, Alimentary pharmacology & therapeutics.

[117]  T E Starzl,et al.  Nonalcoholic cirrhosis associated with neuropsychological dysfunction in the absence of overt evidence of hepatic encephalopathy. , 1984, Gastroenterology.

[118]  D. Häussinger,et al.  Hepatic encephalopathy: clinical aspects and pathogenetic concept. , 2013, Archives of biochemistry and biophysics.

[119]  M. Hashizume,et al.  Laparoscopic disconnection of a huge paraumbilical vein shunt for portosystemic encephalopathy. , 2007, Surgical laparoscopy, endoscopy & percutaneous techniques.

[120]  R. Butterworth,et al.  Increased Density of Catalytic Sites and Expression of Brain Monoamine Oxidase A in Humans with Hepatic Encephalopathy , 1997, Journal of neurochemistry.

[121]  Karin Weissenborn,et al.  The treatment of hepatic encephalopathy , 2007, Metabolic Brain Disease.

[122]  E. Kass,et al.  TREATMENT OF HEPATIC ENCEPHALOPATHY BY ALTERATION OF INTESTINAL FLORA WITH LACTOBACILLUS ACIDOPHILUS. , 1965, Lancet.

[123]  N. Klöcker,et al.  Synaptic plasticity in hepatic encephalopathy - a molecular perspective. , 2013, Archives of biochemistry and biophysics.

[124]  Reversible periodic alternating gaze deviation in hepatic encephalopathy , 1995, Neurology.

[125]  J Hennig,et al.  Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. , 1994, Gastroenterology.

[126]  A. Saad,et al.  METABOLIC STUDIES WITH THE DIURETIC TRIAMTERENE IN PATIENTS WITH CIRRHOSIS AND ASCITES. , 1964, The New England journal of medicine.

[127]  Antonio Gasbarrini,et al.  Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute‐on‐chronic liver failure: The RELIEF trial , 2013, Hepatology.

[128]  Hans Schomerus,et al.  Quality of Life in Cirrhotics with Minimal Hepatic Encephalopathy , 2001, Metabolic Brain Disease.

[129]  Wei Zheng,et al.  Relationship Between Changes in Brain MRI and 1H-MRS, Severity of Chronic Liver Damage, and Recovery After Liver Transplantation , 2009, Experimental biology and medicine.

[130]  B. Sharma,et al.  Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy , 2010, European journal of gastroenterology & hepatology.

[131]  K. Takeda,et al.  Improvement of regional cerebral blood flow after oral intake of branched-chain amino acids in patients with cirrhosis. , 2005, World journal of gastroenterology.

[132]  D. Rockey,et al.  Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy , 2014, Hepatology.

[133]  D. Skene,et al.  Night‐time sleep disturbance does not correlate with neuropsychiatric impairment in patients with cirrhosis , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[134]  A. Tomasello,et al.  Successful Embolization of a Spontaneous Mesocaval Shunt Using the Amplatzer Vascular Plug II , 2010, CardioVascular and Interventional Radiology.

[135]  W. Sibbitt,et al.  Proton MR spectroscopic measurement of neurometabolites in hepatic encephalopathy during oral lactulose therapy. , 1998, AJNR. American journal of neuroradiology.

[136]  Tabershaw Ir,et al.  Benzene and leukaemia. , 1977 .

[137]  D. Einstadter,et al.  A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis , 2017, Digestive Diseases and Sciences.

[138]  C. Zauner,et al.  Partial pressure of ammonia versus ammonia in hepatic encephalopathy , 2000, Hepatology.

[139]  S. Schiff,et al.  Electroencephalographic staging of hepatic encephalopathy by an artificial neural network and an expert system 1 , 2005, Neurophysiologie Clinique/Clinical Neurophysiology.

[140]  D. Shawcross,et al.  Inflammation and hepatic encephalopathy. , 2013, Archives of biochemistry and biophysics.

[141]  N.J. Shah,et al.  Quantitative cerebral water content mapping in hepatic encephalopathy , 2008, NeuroImage.

[142]  Brendan McGuire,et al.  Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis , 2007, Hepatology.

[143]  D. Rockey,et al.  Hepatic Encephalopathy: Pharmacological Therapies Targeting Ammonia , 2016, Seminars in Liver Disease.

[144]  L. Seeff,et al.  Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. , 1977, Gastroenterology.

[145]  M. Vergara,et al.  Treatment of hepatic encephalopathy , 1997, The Lancet.

[146]  P. Kaplan.  The EEG in Metabolic Encephalopathy and Coma , 2004, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[147]  R. Buchert,et al.  Radiotracer imaging studies in hepatic encephalopathy: ISHEN practice guidelines , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[148]  M. Mcphail,et al.  Meta-analysis: the diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy , 2013, Alimentary pharmacology & therapeutics.

[149]  S. Hori,et al.  Portal-systemic encephalopathy: presence of basal ganglia lesions with high signal intensity on MR images. , 1991, Radiology.

[150]  K. Weissenborn,et al.  Bradykinesia in minimal hepatic encephalopathy is due to disturbances in movement initiation. , 2003, Journal of hepatology.

[151]  M. Morgan,et al.  Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. , 2017, The Cochrane database of systematic reviews.

[152]  R. Butterworth,et al.  Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. , 1999, Gastroenterology.

[153]  H. Hodkinson.  Evaluation of a mental test score for assessment of mental impairment in the elderly. , 1972, Age and ageing.

[154]  K Weissenborn,et al.  Neuropsychological characterization of hepatic encephalopathy. , 2001, Journal of hepatology.

[155]  R. Jalan,et al.  Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. , 2004, Clinical science.

[156]  J. Hennig,et al.  Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. , 1997, Gastroenterology.

[157]  V. Felipo,et al.  Oral administration of sildenafil restores learning ability in rats with hyperammonemia and with portacaval shunts , 2005, Hepatology.

[158]  J. A. Arranz,et al.  Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients , 2016, Therapeutic advances in gastroenterology.

[159]  Y. Joshi,et al.  Auditory P300 event‐related potentials and number connection test for evaluation of subclinical hepatic encephalopathy in patients with cirrhosis of the liver: A follow‐up study , 2001, Journal of gastroenterology and hepatology.

[160]  M. Plauth,et al.  ESPEN Guidelines on Enteral Nutrition: Liver disease. , 2006, Clinical nutrition.

[161]  A. Schnitzler,et al.  Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[162]  M. Dam,et al.  18F-fluorodeoxyglucose positron emission tomography study of brain metabolism in cirrhosis: effect of liver transplantation. , 1999, Transplantation proceedings.

[163]  M. Morgan,et al.  Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study. , 1989, Journal of hepatology.

[164]  A. Lockwood,et al.  Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998 , 2002, Hepatology.

[165]  J. Vinel,et al.  Pre‐transjugular intrahepatic portosystemic shunts (TIPS) prediction of post‐TIPS overt hepatic encephalopathy: The Critical Flicker Frequency is more accurate than psychometric tests , 2014, Hepatology.

[166]  H Schomerus,et al.  Latent portasystemic encephalopathy , 1981, Digestive Diseases and Sciences.

[167]  Sara Montagnese,et al.  Disruption of smooth pursuit eye movements in cirrhosis: Relationship to hepatic encephalopathy and its treatment , 2005, Hepatology.

[168]  U. de Girolami,et al.  Neuropathology of liver transplantation. , 1995, Clinical neuropathology.

[169]  R. Butterworth,et al.  Neurobiology of ammonia , 2002, Progress in Neurobiology.

[170]  J. Lai,et al.  Brain α‐Ketoglutarate Dehydrogenase Complex: Kinetic Properties, Regional Distribution, and Effects of Inhibitors , 1986, Journal of neurochemistry.

[171]  J. Bircher,et al.  mechanism of the excessive sedative response of cirrhotics to benzodiazepines: Model experiments with triazolam , 1987, Hepatology.

[172]  Y. Inoue,et al.  Leucine stimulates the secretion of hepatocyte growth factor by hepatic stellate cells. , 2002, Biochemical and biophysical research communications.

[173]  K. Saeian,et al.  Testing for minimal hepatic encephalopathy in the United States: An AASLD survey , 2007, Hepatology.

[174]  R. Esteban,et al.  Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. , 2004, Journal of hepatology.

[175]  P. Angeli,et al.  Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. , 2001, Journal of hepatology.

[176]  M. Morgan,et al.  Characteristics of Minimal Hepatic Encephalopathy , 2004, Metabolic Brain Disease.

[177]  C. Zwingmann,et al.  Effects of ammonia on high affinity glutamate uptake and glutamate transporter EAAT3 expression in cultured rat cerebellar granule cells , 2003, Neurochemistry International.

[178]  A. Farcomeni,et al.  Hepatic encephalopathy expands the predictivity of model for end‐stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts , 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[179]  L. Caregaro,et al.  Study on the Sternberg Paradigm in Cirrhotic Patients Without Overt Hepatic Encephalopathy , 1998, Metabolic Brain Disease.

[180]  B. Sharma,et al.  An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy , 2008, European journal of gastroenterology & hepatology.

[181]  Manuel Romero-Gómez,et al.  Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis. , 2015, Gastroenterology.

[182]  A. Drewes,et al.  New spectral thresholds improve the utility of the electroencephalogram for the diagnosis of hepatic encephalopathy , 2016, Clinical Neurophysiology.

[183]  J. Cummings,et al.  Nitrogen in fecal bacterial, fiber, and soluble fractions of patients with cirrhosis: effects of lactulose and lactulose plus neomycin. , 1987, The Journal of laboratory and clinical medicine.

[184]  M. Navasa,et al.  Prognostic significance of hepatic encephalopathy in patients with cirrhosis. , 1999, Journal of hepatology.

[185]  S. Kulkarni,et al.  Use of model for end‐stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[186]  W. Hop,et al.  Subclinical hepatic encephalopathy impairs daily functioning , 1998, Hepatology.

[187]  M. Vlieger,et al.  Objective measurement of hepatic encephalopathy by means of automated EEG analysis. , 1984, Electroencephalography and clinical neurophysiology.

[188]  R. Dempsey,et al.  GeneChip® analysis shows altered mRNA expression of transcripts of neurotransmitter and signal transduction pathways in the cerebral cortex of portacaval shunted rats , 2002, Journal of neuroscience research.

[189]  P. Angeli,et al.  Cognitive impairment and electroencephalographic alterations before and after liver transplantation: What is reversible? , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[190]  R. Groszmann,et al.  Long‐term hemodynamic effects of ketanserin, a 5‐hydroxytryptamine blocker, in portal hypertensive patients , 1989, Hepatology.

[191]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.

[192]  Simpson Ma.  A mythology of medical education. , 1974 .

[193]  C. Loguercio,et al.  Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. , 1995, Journal of hepatology.

[194]  J. Raskind,et al.  The Role of Carnitine Supplementation during Valproic Acid Therapy , 2000, The Annals of pharmacotherapy.

[195]  D. Krieger,et al.  Neuropsychiatric profile and hyperintense globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis. , 1996, Gastroenterology.

[196]  Thomas A Hammeke,et al.  Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. , 2008, Gastroenterology.

[197]  R. Dhiman,et al.  Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis , 2001, Journal of gastroenterology and hepatology.

[198]  G. D’Amico,et al.  Survival and prognostic indicators in compensated and decompensated cirrhosis , 1986, Digestive Diseases and Sciences.

[199]  M. Merli,et al.  Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients. , 1990, Journal of clinical gastroenterology.

[200]  R. Cunha,et al.  Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade , 2005, Purinergic Signalling.

[201]  B. Gómez-Anson,et al.  Hyponatremia Is a Risk Factor of Hepatic Encephalopathy in Patients With Cirrhosis: A Prospective Study With Time-Dependent Analysis , 2009, The American Journal of Gastroenterology.

[202]  D. Fan,et al.  Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: A systematic review , 2011, Journal of gastroenterology and hepatology.

[203]  M. Morgan,et al.  Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta‐analysis , 2016, Hepatology.

[204]  F. Poordad,et al.  Review article: the burden of hepatic encephalopathy , 2007, Alimentary pharmacology & therapeutics.

[205]  J. Villeneuve,et al.  Surgical treatment of severe postshunt hepatic encephalopathy , 2005, World Journal of Surgery.

[206]  E. Björnsson,et al.  Renal function and cognitive impairment in patients with liver cirrhosis , 2007, Scandinavian journal of gastroenterology.

[207]  H. Schomerus,et al.  Neuropsychological Aspects of Portal-Systemic Encephalopathy , 1998, Metabolic Brain Disease.

[208]  B. Lössner,et al.  Correlations between zinc, amino acids and ammonia in liver cirrhosis. , 1989, Zeitschrift fur Gastroenterologie.

[209]  J. Kondrup,et al.  Long-term oral refeeding of patients with cirrhosis of the liver , 1995, British Journal of Nutrition.

[210]  O. Riggio,et al.  Emerging drugs for hepatic encephalopathy , 2009, Expert opinion on emerging drugs.

[211]  Norbert Hilger,et al.  Hepatic encephalopathy and fitness to drive. , 2009, Gastroenterology.

[212]  Carlos Guarner,et al.  Minimal Hepatic Encephalopathy Is Associated With Falls , 2011, The American Journal of Gastroenterology.

[213]  C. Randolph,et al.  Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[214]  K. Weissenborn.  Challenges in Diagnosing Hepatic Encephalopathy , 2014, Neurochemical Research.

[215]  D. Häussinger,et al.  Gene expression profiling in the cerebral cortex of patients with cirrhosis with and without hepatic encephalopathy , 2013, Hepatology.

[216]  C. Randolph,et al.  Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[217]  R. Kerlan,et al.  Techniques for Transjugular Intrahepatic Portosystemic Shunt Reduction and Occlusion. , 2016, Techniques in vascular and interventional radiology.

[218]  D. Aprile,et al.  A low‐cost, user‐friendly electroencephalographic recording system for the assessment of hepatic encephalopathy , 2016, Hepatology.

[219]  N. Chu,et al.  Evoked potentials in liver diseases , 1997, Journal of gastroenterology and hepatology.

[220]  A. Stracciari,et al.  Minimal hepatic encephalopathy: longitudinal effects of liver transplantation. , 2004, Archives of neurology.

[221]  J. Kulisevsky,et al.  Magnetic resonance imaging pallidal hypersignal in cirrhotic subjects , 1996, Hepatology.

[222]  M. Romero-Gómez,et al.  Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. , 2004, Journal of hepatology.

[223]  The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis , 2003, Hepatology.

[224]  W. Kim,et al.  Hepatic encephalopathy as a predictor of survival in patients with end‐stage liver disease , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[225]  E. S. May,et al.  The slowed brain: cortical oscillatory activity in hepatic encephalopathy. , 2013, Archives of biochemistry and biophysics.

[226]  F. Schliess,et al.  Pathogenetic mechanisms of hepatic encephalopathy , 2008, Gut.

[227]  Andres F Carrion,et al.  Endovascular Management of Refractory Hepatic Encephalopathy Complication of Transjugular Intrahepatic Portosystemic Shunt (TIPS): Comprehensive Review and Clinical Practice Algorithm , 2016, CardioVascular and Interventional Radiology.

[228]  F. Galvano,et al.  Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy , 2010, European journal of gastroenterology & hepatology.

[229]  K. Weissenborn,et al.  Qualifying and quantifying minimal hepatic encephalopathy , 2016, Metabolic Brain Disease.

[230]  F. Weber.  Lactulose and combination therapy of hepatic encephalopathy: the role of the intestinal microflora. , 1996, Digestive diseases.

[231]  Khader M Hasan,et al.  Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy , 2006, Hepatology.

[232]  D. Rockey,et al.  Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. , 2014, JAMA internal medicine.

[233]  M. Morgan,et al.  Therapeutic studies in hepatic encephalopathy , 2007, Metabolic Brain Disease.

[234]  H. Sørensen,et al.  Clinical course of alcoholic liver cirrhosis: A Danish population‐based cohort study , 2010, Hepatology.

[235]  P. Andersen,et al.  Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients. , 2015, Journal of hepatology.

[236]  M. Norenberg,et al.  Ammonia downregulates GLAST mRNA glutamate transporter in rat astrocyte cultures , 1999, Neuroscience Letters.

[237]  Jimmy D Bell,et al.  Cerebral Phosphorus‐31 magnetic resonance spectroscopy in patients with chronic hepatic encephalopathy , 1994, Hepatology.

[238]  M. Merli,et al.  Peripheral and Splanchnic Indole and Oxindole Levels in Cirrhotic Patients: A Study on the Pathophysiology of Hepatic Encephalopathy , 2010, The American Journal of Gastroenterology.

[239]  À. Rovira,et al.  The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. , 2001, Journal of hepatology.

[240]  M. Norenberg,et al.  Combined Effects of Ammonia and Manganese on Astrocytes in Culture , 2004, Neurochemical Research.

[241]  Ching-Po Lin,et al.  Reestablishing Brain Networks in Patients without Overt Hepatic Encephalopathy after Liver Transplantation , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[242]  P. Angeli,et al.  Hyponatremia in cirrhosis: Results of a patient population survey , 2006, Hepatology.

[243]  R. Butterworth,et al.  Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy , 1989, Neurochemical Research.

[244]  A. Burroughs,et al.  Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: A multicenter survey on safety and efficacy , 2013, Hepatology.

[245]  A. Sanyal,et al.  Predictors of the recurrence of hepatic encephalopathy in lactulose‐treated patients , 2010, Alimentary pharmacology & therapeutics.

[246]  Y. Dagon,et al.  Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP‐activated protein kinase , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[247]  G. Marchesini,et al.  Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. , 2003, Gastroenterology.

[248]  E. Tolosa,et al.  Hyperintense globus pallidus on T1‐weighted MRI in cirrhotic patients is associated with severity of liver failure , 1993, Neurology.

[249]  Praveen Sharma,et al.  Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis. , 2010, Hepatobiliary & pancreatic diseases international : HBPD INT.

[250]  P. Hayes,et al.  Psychological outcome and quality of life following liver transplantation: A prospective, national, single‐center study , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[251]  J. Vincent,et al.  Severe sepsis in cirrhosis , 2009, Hepatology.

[252]  R. Butterworth.  Neurosteroids in hepatic encephalopathy: Novel insights and new therapeutic opportunities , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[253]  T. Reynolds,et al.  Cerebrospinal fluid glutamine as a measure of hepatic encephalopathy. , 1971, Archives of internal medicine.

[254]  P. Hayes,et al.  Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS , 2002, Hepatology.